Literature DB >> 15540776

Unilateral nephrectomy as palliative therapy in an infant with autosomal recessive polycystic kidney disease.

Aseem R Shukla1, Darcie A Kiddoo, Douglas A Canning.   

Abstract

Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD) implies a dire prognosis. Neonates affected by the more severe variants of ARPKD suffer respiratory failure caused by massive kidneys that restrict diaphragmatic expansion and result in pulmonary hypoplasia. Afflicted infants who survive the neonatal period and gain adequate respiratory function may subsequently suffer from an inability to tolerate enteral nutrition due to abdominal compression from the massive kidney and the systemic effects of renal compromise. Palliative unilateral or bilateral nephrectomy may be considered in rare instances to facilitate pulmonary expansion and gastrointestinal function. We report on an infant with severe ARPKD who was able to tolerate enteral nutrition only after left nephrectomy.

Entities:  

Mesh:

Year:  2004        PMID: 15540776     DOI: 10.1097/01.ju.0000142025.80132.2f

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects.

Authors:  Erum A Hartung; Lisa M Guay-Woodford
Journal:  Pediatrics       Date:  2014-08-11       Impact factor: 7.124

Review 2.  [Early bilateral nephrectomy in neonatal autosomal recessive polycystic kidney disease : Improved prognosis or unnecessary effort?]

Authors:  S Riechardt; M Koch; J Oh; M Fisch
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

3.  Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference.

Authors:  Lisa M Guay-Woodford; John J Bissler; Michael C Braun; Detlef Bockenhauer; Melissa A Cadnapaphornchai; Katherine M Dell; Larissa Kerecuk; Max C Liebau; Maria H Alonso-Peclet; Benjamin Shneider; Sukru Emre; Theo Heller; Binita M Kamath; Karen F Murray; Kenneth Moise; Eric E Eichenwald; Jacquelyn Evans; Roberta L Keller; Louise Wilkins-Haug; Carsten Bergmann; Meral Gunay-Aygun; Stephen R Hooper; Kristina K Hardy; Erum A Hartung; Randi Streisand; Ronald Perrone; Marva Moxey-Mims
Journal:  J Pediatr       Date:  2014-07-09       Impact factor: 4.406

4.  Early bilateral nephrectomy in infantile autosomal recessive polycystic kidney disease.

Authors:  Tamara Mary Mallett; Emma O'Hagan; Karl Gerard McKeever
Journal:  BMJ Case Rep       Date:  2015-12-15

5.  Risk factors for post-nephrectomy hypotension in pediatric patients.

Authors:  Kentaro Nishi; Koichi Kamei; Masao Ogura; Mai Sato; Sho Ishiwa; Yoko Shioda; Chikako Kiyotani; Kimikazu Matsumoto; Kandai Nozu; Kenji Ishikura; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2021-05-14       Impact factor: 3.714

Review 6.  Autosomal Recessive Polycystic Kidney Disease-The Clinical Aspects and Diagnostic Challenges.

Authors:  Dorota Wicher; Łukasz Obrycki; Irena Jankowska
Journal:  J Pediatr Genet       Date:  2020-07-29

7.  Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).

Authors:  Kathrin Burgmaier; Gema Ariceta; Martin Bald; Anja Katrin Buescher; Mathias Burgmaier; Florian Erger; Michaela Gessner; Ibrahim Gokce; Jens König; Claudia Kowalewska; Laura Massella; Antonio Mastrangelo; Djalila Mekahli; Lars Pape; Ludwig Patzer; Alexandra Potemkina; Gesa Schalk; Raphael Schild; Rukshana Shroff; Maria Szczepanska; Katarzyna Taranta-Janusz; Marcin Tkaczyk; Lutz Thorsten Weber; Elke Wühl; Donald Wurm; Simone Wygoda; Ilona Zagozdzon; Jörg Dötsch; Jun Oh; Franz Schaefer; Max Christoph Liebau
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

Review 8.  Early clinical management of autosomal recessive polycystic kidney disease.

Authors:  Max Christoph Liebau
Journal:  Pediatr Nephrol       Date:  2021-02-17       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.